|

Unveiling New Frontiers in Cancer Treatment: Exploring Immunotherapy

Unveiling New Frontiers in Cancer Treatment: Exploring Immunotherapy

Doctors have found new ways to fight cancer that use our body’s natural defenses. These new treatments are exploring immunotherapy. They help our immune system, which is like our body’s defense team, to fight cancers like mesothelioma.

Understanding Special Proteins

In our bodies, there are proteins called checkpoints. They help our immune system know when to attack harmful cells like cancer and when to leave healthy cells alone. But sometimes, cancer tricks these checkpoints and hides from our immune system.

Scientists made special medicines called immune checkpoint inhibitors (ICIs). These medicines help our immune system work better against cancers like mesothelioma. They stop the tricks that cancer uses to hide from our body’s defenses.

Finding New Helpers

Even though these medicines are helpful, not everyone’s body reacts the same way. Scientists are looking for new checkpoints in our body that could help fight cancer better. They found some new ones like NKG2A, TIGIT, B7-H6, Galectin-3, and TIM-3. These could be important in helping our body fight cancer in new ways.

Using these medicines has been great progress, but there are still challenges. Some people don’t respond well to these medicines. But finding these new checkpoints gives hope for better treatments in the future.

Doctors are trying these new medicines in different ways to help patients with different types of cancers, including mesothelioma. Combining these medicines with other treatments is also making a big difference for people fighting cancer.

Doctors are learning a lot about how our body’s defenses can fight cancer. These new discoveries about checkpoints are making treatment better. Even though there are challenges, scientists are hopeful that these discoveries will help more people beat cancer in the future.

Source:

Patwekar, Mohsina, Nouroz Sehar, Faheem Patwekar, Anuradha Medikeri, Shafat Ali, Rana M Aldossri, and Muneeb U Rehman. “Novel Immune Checkpoint Targets: A Promising Therapy for Cancer Treatments.” International Immunopharmacology 126 (January 5, 2024): 111186. https://doi.org/10.1016/j.intimp.2023.111186.

Similar Posts

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…

  • | |

    Macrophages May Hold Key to Fighting Mesothelioma

    Researchers in Western Australia are investigating new ways of bolstering the immune system in an effort to fight cancers like mesothelioma. Like most types of cancer, malignant mesothelioma occurs primarily in people over 65. That is also the time in life when the immune system typically weakens. Researchers from Curtin University and the University of Western Australia say it is no coincidence that people become more susceptible to mesothelioma as their immunity wanes. In addition to age-related immune dysfunction, mesothelioma patients experience a further decline in immunity caused by the growing tumor itself. To better understand the connection between declining immunity and the onset of mesothelioma, the researchers are focusing on a particular type of immune system cell called a macrophage….

  • | |

    Mesothelioma Study Could Improve Immunotherapy

    Scientists have made an important discovery about a component of the immune system that could have an impact on mesothelioma, one of the rarest and most aggressive cancers. Although mesothelioma is rare, it claims about 2,500 lives in the U.S. annually. Scientists around the globe are searching for a method to keep this cancer from spreading across the membranes that surround the lungs or line the abdomen. As mesothelioma tumors on these membranes grow larger, the likelihood that the cancer will spread to the lungs or other internal organs increases. The immune system is designed to help stop the spread of invaders or out-of-control cancer cells. One immune cell, the Natural Killer or NK cell, is known to exert an anti-tumor effect…

  • | |

    Mesothelioma Vaccine Enters Phase 2 Testing

    The makers of a new cancer vaccine say they have enrolled the first mesothelioma patients in a study that will combine their drug with chemotherapy against this virulent cancer. The drug, currently known as CRS-207, is manufactured by Aduro Bio Tech, Inc. According to a company press release, CRS-207 is based on an attenuated (made less potent) version of Listeria monocytogenes, bacteria found in soil and water than can cause the food borne illness, Listeriosis. To make CRS-207, scientists at Aduro genetically modified the Listeria monocytogenes in order to produce a powerful immune response against cells that produce mesothelin. Mesothelin is a tumor-associated antigen produced by several types of cancer cells, including mesothelioma cells. Because it works in conjunction with the body’s…

  • |

    Immunotherapy for Mesothelioma Shows Promise

    Despite the continuing efforts of researchers around the world, there is currently no standardized cure for mesothelioma. The asbestos-linked cancer is fast-growing and often resistant to conventional therapies. But a growing number of studies have pointed to the value of unconventional treatments like immunotherapy for mesothelioma. Immunotherapy refers to any treatment protocol which aims to harness the body’s own immune system to fight cancer cells.  In a recent article in The Lancet Oncology, two National Cancer Institute researchers summarized some of the most promising immunotherapy approaches now being investigated for mesothelioma: In dendritic cell-based immunotherapy, dendritic cells are harvested from the patient. Outside the body, these cells are stimulated to activate a cytotoxic response against cancer cells.  When they are…

  • | |

    Immunotherapy May Improve Chemotherapy for Mesothelioma

    A treatment designed to inhibit a cell protein called CTLA-4 may improve the effectiveness of chemotherapy for mesothelioma. Chemotherapy is considered a front-line treatment for mesothelioma, although it is only moderately effective.  Because mesothelioma is a highly aggressive cancer of the mesothelium, chemotherapy is often used as part of a multimodality therapeutic approach. Increasingly, immunotherapy, which involves manipulation of the genes and immune system, is also part of the treatment approach. CTLA-4 is the name for both a protein and the gene that is responsible for producing it.  A recent published study tested the theory that knocking down cellular production of the CTLA-4 protein could slow tumor growth and stimulate the immune system between rounds of chemotherapy. To test the…